Refine
Has Fulltext
- yes (107)
Is part of the Bibliography
- yes (107)
Year of publication
Document Type
- Journal article (107) (remove)
Language
- English (107) (remove)
Keywords
- therapeutic drug monitoring (4)
- chemistry (3)
- human (3)
- pharmacokinetics (3)
- polyphenols (3)
- population pharmacokinetics (3)
- positron emission tomography (3)
- protein binding (3)
- synthesis (3)
- ARONJ (2)
- Alzheimer’s disease (2)
- Chemie (2)
- Ernährung (2)
- Medizin (2)
- S-ADAPT (2)
- allometric scaling (2)
- azobenzenes (2)
- body composition (2)
- body size (2)
- butyrylcholinesterase (2)
- capillary electrophoresis (2)
- crystal structure (2)
- cystic fibrosis patients (2)
- cytochrome P450 3A4 (CYP3A4) (2)
- dendritic cells (2)
- drug design (2)
- drugs (2)
- drug–drug interactions (DDIs) (2)
- estrogens (2)
- gene expression (2)
- graft versus host disease (2)
- healthy volunteers (2)
- human breast (2)
- kinetics (2)
- leishmaniasis (2)
- medicine (2)
- multiple linear regression (2)
- natural products (2)
- norepinephrine transporter (2)
- nutrition (2)
- octopamine (2)
- osteoarthritis (2)
- osteonecrosis of the jaw (2)
- osteoradionecrosis (2)
- physiologically based pharmacokinetic (PBPK) modeling (2)
- solubility (2)
- strategy (2)
- structure-activity relationships (2)
- sympathetic nervous system (2)
- therapy (2)
- thermogenesis (2)
- ultrafiltration (2)
- 1 (1)
- 2,5-diketopiperazines (1)
- 2-Thiazaphospholidines (1)
- 2-chloro (1)
- 2-halo (1)
- 2-imino- (1)
- 3 (1)
- 77-LH-28-1 (1)
- AAA+ ATPase p97 (1)
- AChE inhibitor (1)
- AD mouse modele (1)
- ADAMTS (1)
- AGP (1)
- AOM/DSS (1)
- Akt/PKB (1)
- Alzheimer's diseas (1)
- Alzheimer's disease (1)
- Alzheimer′s disease (1)
- Analytical Quality by Design (1)
- Asymmetrie (1)
- Aziridines (1)
- BRAF mutation (1)
- Benzimidazole (1)
- Burkholderia pseudomallei Mip (1)
- CAD detection (1)
- CO‐releasing molecules (CORMs) (1)
- CYP2C9 (1)
- CYP3A4 (1)
- Cabozantinib (1)
- Candida albicans (1)
- Candida auris (1)
- Cecropia telenitida (1)
- Charged aerosol detector (CAD) (1)
- Citrus (1)
- Commercial preparations (1)
- Contaminants (1)
- Cutaneous leishmaniasis (1)
- DNA-encoded library synthesis (1)
- DNA-tagged amines (1)
- Enterobacteriaceae (1)
- Eriodictyon californicum (1)
- Escherichia coli (1)
- FV45 (1)
- Fatty acids (1)
- Flavonoids (1)
- G-protein coupled receptor (1)
- GABA (1)
- GABAB receptor agonists (1)
- GABA\(_{A}\) receptor (1)
- GABA\(_{B}\) (1)
- Geschichte (1)
- Gradient boosted trees (GBT) (1)
- HNSCC (1)
- HPLC–MS (1)
- High-performance liquid chromatography (HPLC) (1)
- Hydrogen-deuterium (1)
- IR (1)
- Ibuprofen (1)
- Imidates (1)
- Imidoyl halides (1)
- Impact-Faktor (1)
- In vivo studies (1)
- JAK inhibitor (1)
- Klebsiella pneumoniae (1)
- Kohlenhydrate (1)
- LC-ESI/MS/MS (1)
- LC-MS/MS (1)
- LpxC inhibitors (1)
- MRONJ (1)
- MYCNv (1)
- Manganese Carbonyl ligands (1)
- Melatonin (1)
- Microglia (1)
- Mip inhibitor (1)
- Mitsunobu (1)
- Natural product hybrids (1)
- ONJ (1)
- Osmunda regalis (1)
- PET (1)
- PPIase (1)
- Paeonia (1)
- Phenolic acids (1)
- Positronen-Emissions-Tomografie (1)
- Pycnogenol (1)
- Quantitative structure-property relationship modeling (QSPR) (1)
- RESP model (1)
- Red Sea (1)
- Robuvit\(^®\) (1)
- Ruxolitinib (1)
- SPECT (1)
- Schistosomiasis (1)
- Spectrofluorimetry (1)
- Staphylococci (1)
- Staphylococcus aureus (1)
- Streptomyces (1)
- Streptomyces axinellae (1)
- Synthesis (1)
- T cell (1)
- T-shaped π-π stacking (1)
- T-shaped π–π stacking (1)
- TDDFT (1)
- Tanzania (1)
- Tryptophan (1)
- Ugi-azide reaction (1)
- V. wallichii (1)
- Valeriana wallichii (1)
- Wissenschaftliches Arbeiten (1)
- Xanomeline (1)
- \(^{1}\)HNMR (1)
- absolute bioavailability (1)
- acebutolol (1)
- acetic acid (1)
- acetones (1)
- acetonitrile (1)
- acetylcholinesterase (1)
- acid value (1)
- acids (1)
- activation (1)
- additive manufacturing (1)
- afatinib (1)
- affinity (1)
- agar diffusion test (1)
- albumin (1)
- alignment (1)
- allergic rhinitis (1)
- allosteric modulation (1)
- amber codon suppression (1)
- amber light (1)
- ampicillin (1)
- amyloid beta (1)
- amyloid-β (Aβ) (1)
- angiotensin II type 1 receptor (1)
- anisotropy (1)
- anti-inflammatory activity (1)
- anti-inflammatory cytokines (1)
- anti-proliferative effects (1)
- anti-schistosomal activity (1)
- anti-trypanosomal (1)
- antibacterial activity (1)
- antibacterials (1)
- antibiotic bone concentration (1)
- antifungal drug (1)
- antileishmanial (1)
- antimicrobial resistance (1)
- antimicrobial stewardship (1)
- antiresorptive drug-related osteonecrosis of the jaw (1)
- antiviral agents (1)
- at-home sampling (1)
- autoinjector (1)
- autophagy (1)
- baclofen (1)
- baclofen homologues (1)
- beta-lactam (1)
- beta-lactam antibiotics (1)
- bile (1)
- bile salt (1)
- binding analysis (1)
- bio-orthogonal chemistry (1)
- bioactivity (1)
- bioassay-guided fractionation (1)
- biochemical simulations (1)
- biocide polyhexamethylene biguanide (1)
- biodiversity (1)
- bioisosterism (1)
- biophysics (1)
- biosensor (1)
- biosynthesis (1)
- bitopic hybrid ligands (1)
- bitopic ligand (1)
- blood brain barrier (1)
- blood plasma (1)
- boat conformation (1)
- bone marrow (1)
- bronchial tissue (1)
- brucei (1)
- caffeic acid bornyl ester (1)
- carbamate (1)
- cardiac innervation imaging (1)
- cardiac neurohormonal system (1)
- cartilage (1)
- cecropia telenitida (1)
- cefotiam (1)
- cell metabolism (1)
- cells (1)
- cerebEND cells (1)
- charged aerosol detector (1)
- chemotherapy (1)
- chenopodium quinoa (1)
- chiral (1)
- chiral resolution (1)
- chiral separation (1)
- cholinergic system (1)
- cholinesterases inhibitors (1)
- chronic IBD model (1)
- circular dichroism (1)
- citrus (1)
- click chemistry (1)
- clinical study (1)
- cofactors (biochemistry) (1)
- cold stress (1)
- colloid (1)
- commercial preparations (1)
- complementary medicine (1)
- computational chemistry (1)
- contaminants (1)
- crithidia fasciulata (1)
- cyclodextrins (1)
- cysteine protease (1)
- cytokine modulation (1)
- cytokine production (1)
- cytotoxicity (1)
- dabrafenib (1)
- decafluoroazobezene (1)
- dehydration (1)
- derivates (1)
- design of experiments (1)
- detector (1)
- device-related infections (1)
- diabetes (1)
- diketopiperazines (1)
- discovery (1)
- dissolution (1)
- dissolution rates (1)
- drug impurities (1)
- drug metabolism (1)
- drug monitoring (1)
- drug-delivery systems (1)
- effector Treg (eTreg) (1)
- electroactive (1)
- electrohydrodynamic (1)
- electrophoresis (1)
- emulsions oil-in-water (1)
- enantiomers (1)
- enantioselectivity (1)
- endothelium (1)
- enoyl-ACP reductase inhibitors (1)
- enterohepatic recirculation (1)
- enzyme kinetics (1)
- enzymes (1)
- ephedrine (1)
- epitope mapping (1)
- ester value (1)
- ethanol (1)
- ethers (1)
- eugenyl cinnamate (1)
- exchange reaction (1)
- excipient (1)
- experimental visceral leishmaniasis (1)
- extraction (1)
- fatty acids (1)
- fenoterol (1)
- field testing (1)
- flavonoid (1)
- flavonoids (1)
- fluorescence polarization (1)
- fluorescence resonance energy transfer (1)
- fluorescent ligands (1)
- fluorescent probes (1)
- fluorine-18 (1)
- fluoroquinolone (1)
- fluticasone propionate (1)
- flux (1)
- forms (1)
- fragment screening (1)
- fragment-based design (1)
- gallotannins (1)
- gastrointestinal (1)
- genetics (1)
- gentamicin sulfate (1)
- glucos metabolism (1)
- glucose (1)
- glutathione (1)
- glycocalyx (1)
- glycolytic flux control (1)
- gradient HPLC–UV (1)
- gut microbiota; bioactivation; polyphenols; complex carbohydrates; tryptophan (1)
- hMSC-TERT (1)
- head and neck carcinoma (1)
- heart failure (1)
- high performance liquid chromatography (1)
- high throughput screening (1)
- high-resolution tandem mass spectrometry (1)
- high-throughput screening (1)
- histamine (1)
- history (1)
- homodimerization (1)
- homology modeling (1)
- honeybee (1)
- honeybees (1)
- human receptor kinetics (1)
- hybrid molecules (1)
- hydnocarpin (1)
- hydrogels (1)
- hydrogen bonding (1)
- hydrogen bonding mycobacterium tuberculosis (1)
- hydrolysis (1)
- hydroxy-dabrafenib (1)
- hypoxia (1)
- hysterectomy (1)
- imaging (1)
- impurity profiling (1)
- in vitro (1)
- in vitro dissolution methods (1)
- in vitro dissolution testing (1)
- in vitro-in vivo correlation (1)
- in vivo dissolution (1)
- information technology (1)
- internal transcribed spacer 2 (1)
- intramolecular Michael addition (1)
- intranasal corticosteroids (1)
- intrinsic metabolism (1)
- invasion (1)
- iodine value (1)
- ipratropium bromide (1)
- isocyanide multicomponent reactions (1)
- isolation (1)
- isomerization (1)
- isosteviol sodium (1)
- jaw bone (1)
- kappa-B activation (1)
- ketamine (1)
- kinase inhibitors (1)
- lactams (1)
- leaves (1)
- linear discriminant analysis (1)
- liquid chromatography electrospray ionization tandem mass spectrometry (1)
- liquid chromatography tandem mass spectrometry (LC-MS/MS (1)
- liquid chromatography-mass spectrometry (1)
- liver impairment (1)
- maceration (1)
- macrophages (1)
- magnesium stearate (1)
- manufacturer (1)
- marine metagenomics (1)
- marine natural products (1)
- marine organisms (1)
- marine sponge (1)
- marine sponges (1)
- maritime pine bark extract (1)
- matrix metalloproteinases (1)
- medicine authentication tools (1)
- melanoma (1)
- melatonin (1)
- metabolic glycoengineering (1)
- metabolic network model (1)
- metabolism (1)
- metastasis (1)
- micelles (1)
- microscopy (1)
- mobile apps (1)
- modified monosaccharides (1)
- molecular mechanics (1)
- molecular systematics (1)
- multicomponent Ugi-type reaction (1)
- muscarinic M1 receptor (1)
- muscarinic acetylcholine receptors (1)
- muscarinic receptors (1)
- natural product (1)
- natural product hybrids (1)
- nerve agent (1)
- neuroblastoma cell (1)
- neuroprotection (1)
- neuroprotectivity (1)
- nicotinic receptors (1)
- nitric oxide (1)
- non-racemic (1)
- nonhuman primates (1)
- novel nepetolactone derivative (1)
- nuclear cardiology (1)
- nuclear magnetic resonance spectroscopy (1)
- oak wood (1)
- oak wood extract (1)
- obtusifolia bertol (1)
- octopamine receptors (1)
- oleanane saponins (1)
- online monitoring system (1)
- opioid ligands (1)
- opioid receptors (1)
- oral anticancer drugs (1)
- oral bioavailability (1)
- oral drug absorption (1)
- oral microbiome (1)
- osimertinib (1)
- oxidative stress (1)
- oxime (1)
- oxygen (1)
- oxytosis/ferroptosis (1)
- parasite (1)
- paromomycin (1)
- patch clamp recording (1)
- pefloxacin (1)
- pentacyclic triterpene (1)
- peptide sensors (1)
- peptide stapling (1)
- perfluoroarylation (1)
- peri-implant disease (1)
- personalized antimicrobial therapy (1)
- pharmaceutical analysis (1)
- pharmacological evaluation (1)
- phosphoglycolate phosphatase (1)
- photocontrol (1)
- photopharmacology (1)
- phylogenetic tree (1)
- phylogeny (1)
- phytochemicals (1)
- pine bark extract (1)
- piperacillin/tazobactam (1)
- plant extract (1)
- plants (1)
- plasma proteins (1)
- podophyllotoxin (1)
- polymer drug interaction (1)
- polymer processing (1)
- polymers (1)
- polysorbate 80 (1)
- posaconazole (1)
- post-operative recovery (1)
- post-surgery recovery (1)
- pressurized microwave‐assisted extraction (1)
- principal component analysis (1)
- pro-inflammatory cytokines (1)
- proliferation (1)
- propionate (1)
- protease inhibition (1)
- protease inhibitors (1)
- proteasome system (1)
- protein engineering (1)
- psidium guajava; (1)
- pulmonary absorption (1)
- purification (1)
- pyridobenzodiazepine (1)
- qPCR (1)
- quality evaluation (1)
- quantitative 1H NMR (1)
- quantum mechanics (1)
- radiotracer (1)
- radiotracer kinetics (1)
- radiotracers (1)
- randomized controlled study (1)
- rat study (1)
- red blood cells (1)
- red fruit oil (1)
- renal cell carcinoma (1)
- renin-angiotensin system (1)
- replica-exchange molecular dynamics (1)
- required hydrophilic–lipophilic balance (1)
- resistance (1)
- response surface (1)
- ribosomal RNA (1)
- ruxolitinib (1)
- sacha inchi oil (1)
- saponification Value (1)
- saturation transfer difference NMR (1)
- schistosoma (1)
- schistosomula (1)
- screening (1)
- secondary structure (1)
- secretion (1)
- sensory chewing gums (1)
- serjanic acid (1)
- serum (1)
- short-range order (1)
- silybin (1)
- simulated intestinal fluid (1)
- single-molecule microscopy (1)
- sisomicin (1)
- solid-state NMR spectroscopy (1)
- spectrofluorimetry (1)
- spray (1)
- staphylococcus aureus (1)
- sterubin (1)
- streptomyces (1)
- structural elucidation (1)
- structure-activity relationship (1)
- structure–activity relationships (1)
- substandard and falsified medicines (1)
- synovial fluid (1)
- system (1)
- tacrine (1)
- tetromycin (1)
- thin-layer chromatography (1)
- thymyl cinnamate (1)
- tofacitinib (1)
- tongue (1)
- topical treatment (1)
- toxicity (1)
- track and trace (1)
- trametinib (1)
- transcriptome (1)
- transport (1)
- treatment regimens (1)
- triacylglycerides (1)
- trypanosoma cruzi (1)
- type 2 diabetes (1)
- unnatural amino acid (1)
- unsaturated fatty acids (1)
- urolithins (1)
- ursolic acid (1)
- vacuoles (1)
- validation (1)
- valsartan (1)
- valtrates (1)
- veterinarians (1)
- veterinary medicine (1)
- volumetric absorptive micro-sampling (VAMS) (1)
- volumetric absorptive microsampling (1)
Institute
- Institut für Pharmazie und Lebensmittelchemie (107) (remove)
Sonstige beteiligte Institutionen
- Apotheke, Universitätsklinikum Würzburg (1)
- Helmholtz Institute for RNA-based Infection Biology (HIRI), Josef-Schneider-Straße 2/D15, DE-9708 Wuerzburg, Germany (1)
- Helmholtz Institute for RNA-based Infection Biology (HIRI), Josef-Schneider-Straße 2/D15, DE-97080 Wuerzburg, Germany (1)
- Johns Hopkins School of Medicine (1)
- Krankenhaushygiene und Antimicrobial Stewardship, Universitätsklinikum Würzburg (1)
- Max Planck Institute for Biophysical Chemistry, Am Faßberg 11, DE-37077 Goetingen, Germany (1)
- Novartis Pharma AG, Lichtstrasse 35, CH-4056 Basel, Switzerland (1)
- Zentraleinheit Klinische Massenspektrometrie (1)
- Zentrallabor, Universitätsklinikum Würzburg (1)
EU-Project number / Contract (GA) number
- 26230120009 (1)
- 296679 (1)
- 311932 (1)
- 314911 (1)
- 701983 (1)
A variety of in vitro dissolution and gastrointestinal transfer models have been developed aiming to predict drug supersaturation and precipitation. Further, biphasic, one-vessel in vitro systems are increasingly applied to simulate drug absorption in vitro. However, to date, there is a lack of combining the two approaches. Therefore, the first aim of this study was to develop a dissolution-transfer-partitioning system (DTPS) and, secondly, to assess its biopredictive power. In the DTPS, simulated gastric and intestinal dissolution vessels are connected via a peristaltic pump. An organic layer is added on top of the intestinal phase, serving as an absorptive compartment. The predictive power of the novel DTPS was assessed to a classical USP II transfer model using a BCS class II weak base with poor aqueous solubility, MSC-A. The classical USP II transfer model overestimated simulated intestinal drug precipitation, especially at higher doses. By applying the DTPS, a clearly improved estimation of drug supersaturation and precipitation and an accurate prediction of the in vivo dose linearity of MSC-A were observed. The DTPS provides a useful tool taking both dissolution and absorption into account. This advanced in vitro tool offers the advantage of streamlining the development process of challenging compounds.
Purpose: A new PET radiotracer \(^{18}\)F-AF78 showing great potential for clinical application has been reported recently. It belongs to a new generation of phenethylguanidine-based norepinephrine transporter (NET)-targeting radiotracers. Although many efforts have been made to develop NET inhibitors as antidepressants, systemic investigations of the structure–activity relationships (SARs) of NET-targeting radiotracers have rarely been performed. Methods: Without changing the phenethylguanidine pharmacophore and 3-fluoropropyl moiety that is crucial for easy labeling, six new analogs of \(^{18}\)F-AF78 with different meta-substituents on the benzene-ring were synthesized and evaluated in a competitive cellular uptake assay and in in vivo animal experiments in rats. Computational modeling of these tracers was established to quantitatively rationalize the interaction between the radiotracers and NET. Results: Using non-radiolabeled reference compounds, a competitive cellular uptake assay showed a decrease in NET-transporting affinity from meta-fluorine to iodine (0.42 and 6.51 µM, respectively), with meta-OH being the least active (22.67 µM). Furthermore, in vivo animal studies with radioisotopes showed that heart-to-blood ratios agreed with the cellular experiments, with AF78(F) exhibiting the highest cardiac uptake. This result correlates positively with the electronegativity rather than the atomic radius of the meta-substituent. Computational modeling studies revealed a crucial influence of halogen substituents on the radiotracer–NET interaction, whereby a T-shaped π–π stacking interaction between the benzene-ring of the tracer and the amino acid residues surrounding the NET binding site made major contributions to the different affinities, in accordance with the pharmacological data. Conclusion: The SARs were characterized by in vitro and in vivo evaluation, and computational modeling quantitatively rationalized the interaction between radiotracers and the NET binding site. These findings pave the way for further evaluation in different species and underline the potential of AF78(F) for clinical application, e.g., cardiac innervation imaging or molecular imaging of neuroendocrine tumors.
Ruxolitinib (RUX) is approved for the treatment of steroid-refractory acute and chronic graft versus host disease (GvHD). It is predominantly metabolized via cytochrome P450 (CYP) 3A4. As patients with GvHD have an increased risk of invasive fungal infections, RUX is frequently combined with posaconazole (POS), a strong CYP3A4 inhibitor. Knowledge of RUX exposure under concomitant POS treatment is scarce and recommendations on dose modifications are inconsistent. A physiologically based pharmacokinetic (PBPK) model was developed to investigate the drug–drug interaction (DDI) between POS and RUX. The predicted RUX exposure was compared to observed concentrations in patients with GvHD in the clinical routine. PBPK models for RUX and POS were independently set up using PK-Sim\(^®\) Version 11. Plasma concentration-time profiles were described successfully and all predicted area under the curve (AUC) values were within 2-fold of the observed values. The increase in RUX exposure was predicted with a DDI ratio of 1.21 (C\(_{max}\)) and 1.59 (AUC). Standard dosing in patients with GvHD led to higher RUX exposure than expected, suggesting further dose reduction if combined with POS. The developed model can serve as a starting point for further simulations of the implemented DDI and can be extended to further perpetrators of CYP-mediated PK-DDIs or disease-specific physiological changes.
Chemical warfare or terrorism attacks with organophosphates may place intoxicated subjects under immediate life-threatening and psychologically demanding conditions. Antidotes, such as the oxime HI-6, which must be formulated as a powder for reconstitution reflecting the molecule’s light sensitivity and instability in aqueous solutions, dramatically improve recovery—but only if used soon after exposure. Muscle tremors, anxiety, and loss of consciousness after exposure jeopardize proper administration, translating into demanding specifications for the dissolution of HI-6. Reflecting the patients’ catastrophic situation and anticipated desire to react immediately to chemical weapon exposure, the dissolution should be completed within ten seconds. We are developing multi-dose and single-dose autoinjectors to reliably meet these dissolution requirements. The temporal and spatial course of dissolution within the various autoinjector designs was profiled colorimetrically. Based on these colorimetric insights with model dyes, we developed experimental setups integrating online conductometry to push experiments toward the relevant molecule, HI-6. The resulting blueprints for autoinjector designs integrated small-scale rotor systems, boosting dissolution across a wide range of viscosities, and meeting the required dissolution specifications driven by the use of these drug products in extreme situations.
The search for new antibiotics against multidrug-resistant (MDR), Gram-negative bacteria is crucial with respect to filling the antibiotics development pipeline, which is subject to a critical shortage of novel molecules. Screening of natural products is a promising approach for identifying antimicrobial compounds hosting a higher degree of novelty. Here, we report the isolation and characterization of four galloylglucoses active against different MDR strains of Escherichia coli and Klebsiella pneumoniae. A crude acetone extract was prepared from Paeonia officinalis Linnaeus leaves, and bioautography-guided isolation of active compounds from the extract was performed by liquid–liquid extraction, as well as open column, flash, and preparative chromatographic methods. Isolated active compounds were characterized and elucidated by a combination of spectroscopic and spectrometric techniques. In vitro antimicrobial susceptibility testing was carried out on E. coli and K. pneumoniae using 2 reference strains and 13 strains hosting a wide range of MDR phenotypes. Furthermore, in vivo antibacterial activities were assessed using Galleria mellonella larvae, and compounds 1,2,3,4,6-penta-O-galloyl-β-d-glucose, 3-O-digalloyl-1,2,4,6-tetra-O-galloyl-β-d-glucose, 6-O-digalloyl-1,2,3,4-tetra-O-galloyl-β-d-glucose, and 3,6-bis-O-digalloyl-1,2,4-tri-O-galloyl-β-d-glucose were isolated and characterized. They showed minimum inhibitory concentration (MIC) values in the range of 2–256 µg/mL across tested bacterial strains. These findings have added to the number of known galloylglucoses from P. officinalis and highlight their potential against MDR Gram-negative bacteria.
Formation of the Aurora-A–MYCN complex increases levels of the oncogenic transcription factor MYCN in neuroblastoma cells by abrogating its degradation through the ubiquitin proteasome system. While some small-molecule inhibitors of Aurora-A were shown to destabilize MYCN, clinical trials have not been satisfactory to date. MYCN itself is considered to be `undruggable' due to its large intrinsically disordered regions. Targeting the Aurora-A–MYCN complex rather than Aurora-A or MYCN alone will open new possibilities for drug development and screening campaigns. To overcome the challenges that a ternary system composed of Aurora-A, MYCN and a small molecule entails, a covalently cross-linked construct of the Aurora-A–MYCN complex was designed, expressed and characterized, thus enabling screening and design campaigns to identify selective binders.
Flavonoids are polyphenolic natural products and have shown significant potential as disease-modifying agents against neurodegenerative disorders like Alzheimer's disease (AD), with activities even in vivo. Hybridization of the natural products taxifolin and silibinin with cinnamic acid led to an overadditive effect of these compounds in several phenotypic screening assays related to neurodegeneration and AD. Therefore, we have exchanged the flavonoid part of the hybrids with different flavonoids, which show higher efficacy than taxifolin or silibinin, to improve the activity of the respective hybrids. Chemical connection between the flavonoid and cinnamic acid was realized by an amide instead of a labile ester bond to improve stability towards hydrolysis. To investigate the influence of a double bond at the C-ring of the flavonoid, the dehydro analogues of the respective hybrids were also synthesized. All compounds obtained show neuroprotection against oxytosis, ferroptosis and ATP-depletion, respectively, in the murine hippocampal cell line HT22. Interestingly, the taxifolin and the quercetin derivatives are the most active compounds, whereby the quercetin derivate shows even more pronounced activity than the taxifolin one in all assays applied. As aimed for, no hydrolysis product was found in cellular uptake experiments after 4 h whereas different metabolites were detected. Furthermore, the quercetin-cinnamic acid amide showed pronounced activity in an in vivo AD mouse model at a remarkably low dose of 0.3 mg/kg.
Amber Light Control of Peptide Secondary Structure by a Perfluoroaromatic Azobenzene Photoswitch
(2023)
The incorporation of photoswitches into the molecular structure of peptides and proteins enables their dynamic photocontrol in complex biological systems. Here, a perfluorinated azobenzene derivative triggered by amber light was site‐specifically conjugated to cysteines in a helical peptide by perfluoroarylation chemistry. In response to the photoisomerization (trans→cis) of the conjugated azobenzene with amber light, the secondary structure of the peptide was modulated from a disorganized into an amphiphilic helical structure.
Azobenzene derivatives with activity against drug‐resistant Candida albicans and Candida auris
(2023)
Increasing resistance against antimycotic drugs challenges anti‐infective therapies today and contributes to the mortality of infections by drug‐resistant Candida species and strains. Therefore, novel antifungal agents are needed. A promising approach in developing new drugs is using naturally occurring molecules as lead structures. In this work, 4,4'‐dihydroxyazobenzene, a compound structurally related to antifungal stilbene derivatives and present in Agaricus xanthodermus (yellow stainer), served as a starting point for the synthesis of five azobenzene derivatives. These compounds prevented the growth of both fluconazole‐susceptible and fluconazole‐resistant Candida albicans and Candida auris strains. Further in vivo studies are required to confirm the potential therapeutic value of these compounds.
Characterization of binding properties of ephedrine derivatives to human alpha-1-acid glycoprotein
(2023)
Most drugs, especially those with acidic or neutral moieties, are bound to the plasma protein albumin, whereas basic drugs are preferentially bound to human alpha-1-acid glycoprotein (AGP). The protein binding of the long-established drugs ephedrine and pseudoephedrine, which are used in the treatment of hypotension and colds, has so far only been studied with albumin. Since in a previous study a stereoselective binding of ephedrine and pseudoephedrine to serum but not to albumin was observed, the aim of this study was to check whether the enantioselective binding behavior of ephedrine and pseudoephedrine, in addition to the derivatives methylephedrine and norephedrine, is due to AGP and to investigate the influence of their different substituents and steric arrangement. Discontinuous ultrafiltration was used for the determination of protein binding. Characterization of ligand-protein interactions of the drugs was obtained by saturation transfer difference nuclear magnetic resonance spectroscopy. Docking experiments were performed to analyze possible ligand-protein interactions. The more basic the ephedrine derivative is, the higher is the affinity to AGP. There was no significant difference in the binding properties between the individual enantiomers and the diastereomers of ephedrine and pseudoephedrine.